摘要
肥胖改变机体代谢状态,显著增加糖尿病、心血管病等多种疾病风险,已经对我国造成严重经济和社会负担,肥胖治疗药物一直是研发热点。2019年以来,FDA批准了PLENITY和Imcivree两种新药用于肥胖治疗。本文对PLENITY和Imcivree这两种药物进行详细介绍,并对目前处于不同研发阶段的其它在研药物进行总结,以期加深对肥胖治疗现状和前景的认识。
Obesity induces the change in body metabolic state and significantly increases the risk of various diseases such as diabetes and cardiovascular diseases. It has already led to severe economic and social burden on our country. Development of obesity treatment drugs is a hot topic at present. Since 2019, FDA has approved two new drugs, PLENITY and Imcivree, for obesity treatment. This article introduces PLENITY and Imcivree in detail, and summarizes other candidate drugs at different research and development stages, which aims to deepen the understanding of the current situation and prospect of obesity treatment.
出处
《临床医学进展》
2021年第11期5138-5143,共6页
Advances in Clinical Medicine
